These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 8497347)

  • 1. Evaluation of a new generation of oral contraceptives. The Advisory Board for the New Progestins.
    Speroff L; DeCherney A
    Obstet Gynecol; 1993 Jun; 81(6):1034-47. PubMed ID: 8497347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.
    Teichmann A
    Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():98-104. PubMed ID: 8574257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Desogestrel, norgestimate, and gestodene: the newer progestins.
    Kaplan B
    Ann Pharmacother; 1995; 29(7-8):736-42. PubMed ID: 8520092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative evaluation of the androgenicity of four low-dose, fixed-combination oral contraceptives.
    Coenen CM; Thomas CM; Borm GF; Rolland R
    Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():92-7. PubMed ID: 8574256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative review of third-generation progestins.
    Kafrissen ME; Corson SL
    Int J Fertil; 1992; 37 Suppl 2():104-15. PubMed ID: 1354657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The new pills: awaiting the next generation of oral contraceptives.
    Klitsch M
    Fam Plann Perspect; 1992; 24(5):226-8. PubMed ID: 1426186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A norgestimate-containing oral contraceptive: review of clinical studies.
    Kafrissen ME
    Am J Obstet Gynecol; 1992 Oct; 167(4 Pt 2):1196-202. PubMed ID: 1415446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Third generation progestagens].
    Belaisch J; Eliakim V
    Contracept Fertil Sex (Paris); 1993 Apr; 21(4):287-93. PubMed ID: 12318226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical aspects of three new progestogens: desogestrel, gestodene, and norgestimate.
    Chez RA
    Am J Obstet Gynecol; 1989 May; 160(5 Pt 2):1296-300. PubMed ID: 2524163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. European Society of Contraception oral contraceptives survey update: birth control methods in "Europe of the 12".
    Serfaty D; Wildemeersch D; Verougstraete A; Creatsas G
    Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():73-9. PubMed ID: 8574253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics of the new progestogens in combination oral contraceptives.
    Rebar RW; Zeserson K
    Contraception; 1991 Jul; 44(1):1-10. PubMed ID: 1832625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic aspects of the new low-dose oral contraceptives.
    Chez RA
    Int J Fertil; 1989 Sep; 34 Suppl():50-4. PubMed ID: 2576259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Influence of progestins on adverse effects of oral contraceptives].
    Wynn V
    Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):425-30. PubMed ID: 12280210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The new era in oral contraception: pills containing gestodene, norgestimate, and desogestrel.
    London RS
    Obstet Gynecol Surv; 1992 Nov; 47(11):777-82. PubMed ID: 1436906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel.
    Jick SS; Kaye JA; Russmann S; Jick H
    Contraception; 2006 Jun; 73(6):566-70. PubMed ID: 16730485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of the androgenicity of progestins in hormonal therapy in women.
    Linn ES
    Clin Ther; 1990; 12(5):447-55. PubMed ID: 2268868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New progestational hormones].
    Köhler G; Göretzlehner G
    Zentralbl Gynakol; 1988; 110(13):801-8. PubMed ID: 2972141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale for new oral contraceptive dosing.
    Williams JK
    Int J Fertil Womens Med; 2004; 49(1):30-5. PubMed ID: 15038507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Side effects of third generation progestagens].
    Sitruk-ware R
    Contracept Fertil Sex (Paris); 1993 Apr; 21(4):295-300. PubMed ID: 12318229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Potential advantages of triphasic combined oral contraceptives in the light of recent epidemiological and endocrinometabolic data].
    Gaspard U; Dubois M
    Contracept Fertil Sex (Paris); 1982 Sep; 10(9):551-60. PubMed ID: 12311606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.